Brand name : Zecyte
Active ingredient : Abiraterone acetate
Strength :250MG
Manufactured by : Cipla
Pack : 250MG-120 tablets in a carton
Category : Anti-neoplastic drug


Zecyte is known as fluoropyrimidine carbamat who having the anti-cancer activity. The drug supplied as oblong and film coated tablet for oral administration, the main ingredient which is used as abiraterone . Zecyte is a systemic prodrug of 5’-deoxy-5-fluorouridine (5’-DFUR) which is changed to 5 fluoro uracil Zecyte is also have anti-metabolite activity and the activity of Zecyte tablet will inhibits the growth of tumor cells and slows their spread in the body. Zecyte is prescription drugs sold under the proper guidance of medical oncologist and pharmacist.

First line therapy of patients with advanced colorectal cancer:
The usual dose of Zecyte is 1250mg/m2 should be taken orally as twice daily (morning and evening dose 2250MG/m2); therapy continue for 2 weeks followed by 1 week rest period given as 3 weeks cycle
Adjuvant therapy for Duke’s colon cancer:
The usual dose of Zecyte is 1250mg/m2 orally as twice daily (morning and evening dose 2250MG/m2); for 2 weeks followed by 1 week given as 3 weeks for total 8 cycles (24 weeks)

Breast cancer

Monotherapy: Recommended dose: 1250mg/m2 should be taken as orally for twice daily In combination with docetaxel; 1250mg/m2 of Zecyte with 75mg/m2 of docetaxel for 3 weeks After a meal the drug Zecyte should be given within 30 minutes

In pediatric

The safety and efficacy of the Zecyte tablets in pediatric patients has not been established


The time to peak plasma level at about 1.5 hours Food reduced both the rate and duration of absorption of Zecyte with mean Cmax and AUC0-∞ reduced by 60% and 35% respectively
The human plasma protein bound to Zecyte is occurs in less than 60%
Bio-activation and metabolism:
Zecyte is largely metabolized to 5-FU enzymatically. In liver, 60 kDa carboxylesterase hydrolyses to 5’-deoxy-5-fluorocytidine. An enzyme which converts 5’-DFCR to 5’-DFUR known as Cytidine deaminase. another an enzyme which involved in the conversion of 5’-DFUR to 5-FU active drug is Thymidine phosphorylase
The route of elimination of Zecyte is occurred through urine 95.5% The mean terminal half life period of Zecyte is 0.75 hour


Enzymes changes capecitabine to 5-fluorouracil (5-FU) in vivo. Both normal and cancer cells metabolize 5-FU to 5-fluoro-2’-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). These metabolites leads to cell damage by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, link to thymidylate synthase (TS) and form a complex of covalently bound ternary. This bounding prohibits the thymidylate from 2’-deoxyuridylate formation. Thymidylate is the required precursor of thymidine triphosphate, which is specifically used for the synthesis of DNA, so that a inadequacy of this mixture can prevent cell division. Second, during the synthesis of RNA the nuclear transcriptional enzymes can mistakenly fused FUTP in place of uridine triphosphate (UTP). This metabolic error can prevent RNA processing and synthesis of protein.


Cardio toxicity: while taking Zecyte, cardio toxicity occurs like; myocardial infarction, angina, dyshythmias, cardiac arrest sudden death, Cardiomyopathy Diarrhea: patients with severe diarrhea should be monitored Dihydropyrimidine dehydrogenase deficiency Dehydration and renal failure Embryo fetal toxicity Mucocutaneous and dermatologic toxicity Hyperbilirubinaemia Hematological problems Care should be taken while using in geriatric patients Hepatic insufficiency Coagulopathy: concomitant with warfarin, anti-coagulant response should be monitored


Zecyte interaction with warfarin and phenprocoumon, bleeding occurs. These events occurred within several days and even a month also Interaction of phenytoin with Zecyte, toxicity related to elevation of phenytoin levels Concomitant use of Leucovorin: the toxicity and concentration of 5-FU increased by Leucovorin. In elderly patients, phenytoin and Leucovorin is administered weekly which may cause; diarrhea, dehydration, enterocolitis which may causes death. other than warfarin, there is no drug interaction occurs while concomitant with CYP2C9 substrates While combination of Zecyte with CYP2C9 substrates Care should be taken


In case of administering Zecyte with food, it leads to reduce the rate and duration of absorption of Zecyte. Zecyte (Abiraterone acetate) tablets should be administered within 30 minutes after food


Renal impairment patients.Patients with hypersensitivity to Zecyte or other components.


If dose is missed then take the dose of Zecyte, must consult with medical oncologist and follow the suggestions Avoid taking self medicate. Or missed dose must be skipped and continue the regular dosing schedule Do not double the dose


Most common side effects : Diarrhea, nausea, anemia, Lymphopenia, head and foot syndrome, edema, fatigue, fever, headache, pain, paresthesia, alopecia, dermatitis, abdominal pain, anorexia, loss of appetite, constipation, dyspepsia, stomatitis, vomiting, neutropenia, thrombocytopenia, dyspnea, bilirubin decreased, eye irritation
Common side effects : Dermatitis , rash, dizziness, headache, Chest pain, weakness, dehydration, dry mouth, dyspepsia, Pruritus, taste disturbance, back pain Post marketing reports: Toxic leukoencephalopathy


Zecyte should be stored at 20℃ to 25℃ (68℉ to 77℉)


Pregnancy category: D Zecyte may cause harm to the fetus. Generally Zecyte should not be recommended in pregnancy or women who are become pregnant

We'd Like to Hear From You!


1., a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.
2. will not dispense any prescription medication without a valid prescription from a licensed physician.
3. If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.
4. The drug information provided in the is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.
5. requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from
6. At, a Caregiver can order prescription medicines on your behalf.

This information should not be used to decide whether to accept this product or any other medicine. Only a health care provider is knowledge and training to decide that a medicine suitable for a specific patient. This information does not support any drug as safe, are effective or approved for the treatment of any patient or health condition. It's simple a brief overview of general information about this product. It does not include all information on possible applications, indications, warnings, precautions, interactions, adverse effects or risks that may be relevant to this product. This information is not specific medical advice and does not replace information obtained from your health care provider. You should check with your health care provider for complete information about the risks and benefits of using this product.